P/E ratio for Oragenics (OGEN)
P/E ratio as of April 2024 (TTM): -0.1767
According to Oragenics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.176672. At the end of 2022 the company had a P/E ratio of -0.9362.
P/E ratio history for Oragenics from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.9362 | -71.95% |
| 2021 | -3.34 | 256% |
| 2020 | -0.9375 | -33.29% |
| 2019 | -1.41 | 103.23% |
| 2018 | -0.6915 | -58.81% |
| 2017 | -1.68 | -51.19% |
| 2016 | -3.44 | -26.62% |
| 2015 | -4.69 | -15.73% |
| 2014 | -5.56 | 12.83% |
| 2013 | -4.93 | 77.89% |
| 2012 | -2.77 | 269.05% |
| 2011 | -0.7509 | -64.36% |
| 2010 | -2.11 | -29.42% |
| 2009 | -2.99 | 102.99% |
| 2008 | -1.47 | -64.13% |
| 2007 | -4.10 | -40.36% |
| 2006 | -6.88 | 251.74% |
| 2005 | -1.95 | -111.17% |
| 2004 | 17.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -5,972.69% | 🇺🇸 USA |
 SIGA Technologies SIGA | 23.1 | -13,192.96% | 🇺🇸 USA |
 OPKO Health
OPK | -4.67 | 2,541.43% | 🇺🇸 USA |
 Nature's Sunshine Products NATR | 68.5 | -38,870.15% | 🇺🇸 USA |
 USANA USNA | 14.0 | -8,029.72% | 🇺🇸 USA |
 Lannett Company LCI | -0.0271 | -84.65% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.